Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma ...

Replimune stock was down 76.88% in pre-market trading on Tuesday, following a 1.94% rally yesterday. The company’s shares ...

Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Replimune Group, Inc. (NASDAQ: REPL) resulting from ...

Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the ...

Replimune Group Stock Performance. Shares of REPL stock opened at $8.76 on Friday. The company’s fifty day simple moving average is $8.69 and its 200-day simple moving average is $11.24.

Replimune Group granted stock options and restricted shares to ten new non-executive employees as part of their incentive plan. Replimune Group, Inc., a clinical stage biotechnology company based ...

Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price […] Replimune Group, Inc. (NASDAQ:REPL ...

About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies.

Research and development expenses included $4.5 million in stock-based compensation expenses for the fiscal fourth quarter and $18.4 million for the fiscal year ended March 31, 2025.